Noncoding RNAs: Different roles in tumorigenesis

Chinese Science Bulletin

Volumn 57, Issue 9, 2012, Pages 959-965

  Lin, Mei ^a   Wu, Jing ^b   Shan, Ge ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

cancer; microRNA; noncoding RNA

Indexed keywords

MAMMALIA;

EID: 84863236972     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-011-4917-x     Document Type: Review

References (77)

1. Carninci P, Kasukawa T, Hayashizaki Y, et al. The transcriptional landscape of the mammalian genome. Science, 2005, 309: 1559-1563.
2. Kapranov P, Willingham A T, Gingeras T R. Genome-wide transcription and the implications for genomic organization. Nat Rev Genet, 2007, 8: 413-423.
3. Calin G A, Dumitru C D, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 2002, 99: 15524-15529.
4. Friedman R C, Farh K K, Burge C B, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 2009, 19: 92-105.
5. Kawasaki H, Taira K. MicroRNA-196 inhibits HOXB8 expression in myeloid differentiation of HL60 cells. Nucleic Acids Symp Ser, 2004, 48: 211-212.
6. Eulalio A, Huntzinger E, Nishihara T. Deadenylation is a widespread effect of miRNA regulation. RNA, 2009, 15: 21-32.
7. Calin G A, Sevignani C. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA, 2004, 101: 2999-3004.
8. Sevignani C, Calin G A. MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci USA, 2007, 104: 8017-8022.
9. Johnson S M, Grosshans H. RAS is regulated by the let-7 microRNA family. Cell, 2005, 120: 635-647.
10. Eis P S, Tam W. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA, 2005, 102: 3627-3632.
11. Ota A, Tagawa H, Karnan S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res, 2004, 64: 3087-3095.
12. Calin G A, Croce C M. MicroRNA signatures in human cancers. Nat Rev Cancer, 2006, 6: 857-866.
13. Lee Y S, Dutta A. MicroRNAs in cancer. Annu Rev Pathol Mech Dis, 2009, 4: 199-227.
14. Ryan B M, Robles A I, Harris C C. Genetic variation in microRNA networks: The implications for cancer research. Nat Rev Cancer, 2010, 10: 389-402.
15. Krützfeldt J, Rajewsky N. Silencing of microRNAs in vivo with "antagomirs". Nature, 2005, 438: 685-689.
16. Ryan B M, Robles A I, Harris C C. Genetic variation in microRNA networks: The implications for cancer research. Nat Rev Cancer, 2010, 10: 389-402.
17. Kwak P B, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Sci, 2010, 101: 2309-2315.
18. Bertone P, Stolc V, Royce T E. Global identification of human transcribed sequences with genome tiling arrays. Science, 2004, 24: 2242-2246.
19. Brannan C I, Dees E C. The product of the H19 gene may function as an RNA. Mol Cell Biol, 1990, 10: 28-36.
20. Brown C J, Ballabio A. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature, 1991, 349: 38-44.
21. Willingham A T, Orth A P. A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. Science, 2005, 309: 1570-1573.
22. Brunkow M E, Tilghman S M. Ectopic expression of the H19 gene in mice causes prenatal lethality. Genes Dev, 1991, 5: 1092-1101.
23. Barsyte-Lovejoy D, Lau S K, Boutros P C. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res, 2006, 66: 5330-5337.
24. Hao Y, Crenshaw T. Tumour-suppressor activity of H19 RNA. Nature, 1993, 365: 764-767.
25. Steenman J C, Rainier S. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet, 1994, 7: 433-439.
26. Moulton T, Crenshaw T. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet, 1994, 7: 440-447.
27. Matouk I J, DeGroot N. The H19 noncoding RNA is essential for human tumor growth. PLoS ONE, 2007, 2: e845.
28. Scott R E, Gao S. De-differentiation-derived mesenchymal stem cells demonstrate selective repression in H19 bioregulatory RNA gene expression. Differentiation, 2005, 73: 294-302.
29. Ayesh S, Matouk I. Possible physiological role of H19 RNA. Mol Carcinog, 2002, 35: 63-74.
30. Yang J, Mani S A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 2004, 117: 927-939.
31. Berteaux N, Lottin S. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem, 2005, 280: 29625-29636.
32. Cai X Z, Cullen B R. The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA, 2007, 13: 313-316.
33. Leighton P A, Saam J R. An enhancer deletion affects both H19 and Igf2 expression. Genes Dev, 1995, 9: 2079-2089.
34. Ekstrom T J, Cui H. Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development, 1995, 121: 309-316.
35. DeBaun M R, Niemitz E L. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am J Hum Genet, 2002, 70: 604-611.
36. Wilkin F, Paquette J. H19 sense and antisense transgenes modify insulinlike growth factor-II mRNA levels. Eur J Biochem, 2000, 267: 4020-4027.
37. Li Y M, Franklin G. The H19 transcript is associated with polysomes and may regulate IGF2 expression intrans. J Biol Chem, 1998, 273: 28247-28252.
38. Toillon R A, Descamps S, Adriaenssens E. Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness. Exp Cell Res, 2005, 310: 176-185.
39. Banet G, Bibi O. Characterization of human and mouse H19 regulatory sequences. Mol Biol Rep, 2000, 27: 157-165.
40. Rinn J L, Kertesz M. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell, 2007, 129: 1311-1323.
41. Gupta R A, Shah N. Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature, 2010, 464: 1071-1076.
42. Tsai M C, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science, 2010, 6: 689-693.
43. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev, 2007, 21: 1050-1063.
44. Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell, 2010, 142: 409-419.
45. Bejerano G. Ultraconserved elements in the human genome. Science, 2004, 304: 1321-1325.
46. Bejerano G. Into the heart of darkness: Large-scale clustering of human noncoding DNA. Bioinformatics, 2004, 20: i40-i48.
47. Calin G A, Liu C G, Ferracin M, et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell, 2007, 12: 215-229.
48. Scaruffi P, Stigliani S, Moretti S, et al. Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer, 2009, 9: 441.
49. Katayama S, Tomaru Y. Antisense transcription in the mammalian transcriptome. Science, 2005, 309: 1564-1566.
50. Capaccioli S, Quattrone A, Schiavone N, et al. A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14; 18) cell lines. Oncogene, 1996, 13: 105-115.
51. Yamamoto T, Manome Y, Nakamura M, et al. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer, 2002, 38: 2316-2324.
52. Cui I, Cui H. Antisense RNAs and epigenetic regulation. Epigenomics, 2010, 2: 139-150.
53. Faghihi M A. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol, 2009, 10: 637-643.
54. Yu W, Gius D, Onyango P, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature, 2008, 451: 202-206.
55. Morris K V. Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genet, 2008, 4: e1000258.
56. Mahmoudi S. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell, 2009, 33: 462-471.
57. Sleutels F, Zwart R, Barlow D P. The noncoding Air RNA is required for silencing autosomal imprinted genes. Nature, 2002, 415: 810-813.
58. Zwart R, Sleutels F, Wutz A, et al. Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes. Genes Dev, 2001, 15: 2361-2366.
59. Lyle R, Watanabe D, te Vruchte D, et al. The imprinted antisense RNA at the Igf2r locus overlaps but does not imprint Mas1. Nat Genet, 2000, 25: 19-21.
60. Winter A G, Sourvinos G, Allison S J, et al. RNA polymerase III transcription TFIIIC2 is overexpressed in ovarian tumours. Proc Natl Acad Sci USA, 2000, 97: 12619-12624.
61. Daly N L, Arvanitis D A, Fairley J A, et al. Deregulation of RNA polymerase III transcription in cervical epithelium in response to high-risk human papillomavirus. Oncogene, 2005, 24: 880-888.
62. Pavon-Eternod M, Gomes S, Geslain R, et al. tRNA over-expression in breast cancer and functional consequences. Nucleic Acids Res, 2009, 37: 7268-7280.
63. Frye M, Watt F M. The RNA methyltransferase Misu (NSun2) mediates myc-induced proliferation and is upregulated in tumors. Curr Biol, 2006, 16: 971-981.
64. Marshall L, Kenneth N S, White R J. Elevated tRNAi Met synthesis can drive cell proliferation and oncogenic transformation. Cell, 2008, 133: 78-89.
65. Mei Y, Yong J, Liu H, et al. tRNA binds to cytochrome c and inhibits caspase activation. Mol Cell, 2010, 37: 668-678.
66. Anderson S, Bankier A T, Barrell B G, et al. Sequence and organization of the human mitochondrial genome. Nature, 1981, 290: 457-465.
67. Fernández-Silva P, Enriquez J A, Montoya J. Replication and transcription of mammalian mitochondrial DNA. Exp Physiol, 2003, 88: 41-56.
68. Clayton D A. Replication and transcription of vertebrate mitochondrial DNA. Annu Rev Cell Biol, 1991, 7: 453-478.
69. Lu J, Sharma L K, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res, 2009, 19: 802-815.
70. Lisa M. Impact of disease-related mitochondrial mutations on tRNA structure and function. Trends Biochem Sci, 2003, 28: 605-611.
71. Villegas J, Zárraga A M, Muller I, et al. A novel chimeric mitochondrial RNA localized in the nucleus of mouse sperm. DNA Cell Biol, 2000, 19: 579-588.
72. Villegas J, Müller I, Arredondo J, et al. A putative RNA editing from U to C in a mouse mitochondrial transcript. Nucleic Acids Res, 2002, 30: 1895-1901.
73. Villegas J, Burzio V, Villota C, et al. Expression of a novel noncoding mitochondrial RNA in human proliferating cells. Nucleic Acids Res, 2007, 35: 7336-7347.
74. Burzio V A, Villota C, Villegas J, et al. Expression of a family of noncoding mitochondrial RNAs distinguishes normal from cancer cells. Proc Natl Acad Sci USA, 2009, 106: 9430-9434.
75. Castelnuovo M, Massone S, Tasso R, et al. An Alu-like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells. FASEB J, 2010, 24: 4033-4046.
76. Christov C P, Trivier E, Krude T. Noncoding human Y RNAs are overexpressed in tumours and required for cell proliferation. Br J Cancer, 2008, 98: 981-988.
77. Gee H E, Buffa F M, Camps C, et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer, 2011, 104: 1168-1177.